RECRUITING

Topical Insulin for Glaucoma

Description

The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic neuropathy, and optic disc drusen).

Conditions

Glaucoma
Talk to us

Related Conditions:

Glaucoma

Study Overview

On this page

Study Details

Study overview

The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic neuropathy, and optic disc drusen).

Topical Insulin for Glaucoma and Optic Neuropathies

Topical Insulin for Glaucoma

Condition
Glaucoma
Intervention / Treatment

-

Contacts and Locations

Palo Alto

Byers Eye Institute at Stanford University, Palo Alto, California, United States, 94303

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Capable to provide informed consent
  • * Diagnosis of optic neuropathy either glaucoma or NAION or optic disc drusen.
  • * Only one eye per patient will be selected as the study eye - if both eyes meet the inclusion criteria, the eye with the worse acuity and /or visual field will be selected. The contralateral eye will be left untouched.
  • * Pregnant or breastfeeding woman
  • * Presence of any ocular pathologies other than glaucoma that contributes to the severe vision loss (retinopathy / maculopathy, severe uveitis, keratopathy, etc.)
  • * Diagnosis of glucose intolerance, type 1 or 2 diabetes mellitus
  • * Inability to perform reliable visual field
  • * Unable to provide informed consent
  • * Unable to complete the tests and follow-ups required by the study

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Stanford University,

Jeffrey L Goldberg, MD, PhD, PRINCIPAL_INVESTIGATOR, Stanford University

Study Record Dates

2025-12-31